Jacobi Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Jacobi Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4M	Sell	65,891 -494	-0.7%	-$28.8K	0.22%	81
2025 Q4	$3.58M	Sell	66,385 -1,824	-3%	-$87.7K	0.21%	88
2025 Q3	$3.08M	Buy	68,209 +1,770	+3%	+$82.7K	0.19%	100
2025 Q2	$3.08M	Buy	66,439 +1,826	+3%	+$89.6K	0.2%	92
2025 Q1	$3.94M	Sell	64,613 -1,169	-2%	-$68.1K	0.29%	62
2024 Q4	$3.72M	Sell	65,782 -3,093	-4%	-$173K	0.28%	65
2024 Q3	$3.56M	Buy	68,875 +821	+1%	+$38.5K	0.27%	72
2024 Q2	$2.83M	Buy	68,054 +6,301	+10%	+$282K	0.25%	78
2024 Q1	$3.35M	Buy	61,753 +16,969	+38%	+$864K	0.31%	54
2023 Q4	$2.3M	Buy	44,784 +339	+0.8%	+$17.8K	0.24%	83
2023 Q3	$2.58M	Buy	44,445 +1,107	+3%	+$67.8K	0.29%	62
2023 Q2	$2.77M	Sell	43,338 -2,483	-5%	-$167K	0.31%	58
2023 Q1	$3.18M	Sell	45,821 -2,002	-4%	-$141K	0.38%	50
2022 Q4	$3.44M	Buy	47,823 +186	+0.4%	+$14K	0.43%	42
2022 Q3	$3.39M	Buy	47,637 +607	+1%	+$44K	0.46%	39
2022 Q2	$3.62M	Buy	47,030 +984	+2%	+$74.9K	0.48%	33
2022 Q1	$3.36M	Sell	46,046 -49,875	-52%	-$3.35M	0.4%	42
2021 Q4	$5.98M	Buy	95,921 +4,111	+4%	+$241K	0.71%	22
2021 Q3	$5.43M	Buy	91,810 +49,370	+116%	+$3.25M	0.69%	21
2021 Q2	$2.84M	Buy	42,440 +6,999	+20%	+$456K	0.37%	42
2021 Q1	$2.24M	Sell	35,441 -386	-1%	-$24K	0.33%	55
2020 Q4	$2.24M	Buy	35,827 +284	+0.8%	+$17.5K	0.35%	49
2020 Q3	$2.14M	Buy	35,543 +4,465	+14%	+$269K	0.38%	49
2020 Q2	$1.84M	Buy	31,078 +522	+2%	+$31.2K	0.34%	55
2020 Q1	$1.74M	Sell	30,556 -1,358	-4%	-$83K	0.37%	51
2019 Q4	$2.05M	Buy	31,914 +6,289	+25%	+$360K	0.37%	56
2019 Q3	$1.33M	Buy	25,625 +3,190	+14%	+$150K	0.26%	75
2019 Q2	$1.02M	Buy	22,435 +9,042	+68%	+$421K	0.21%	94
2019 Q1	$639K	Buy	13,393 +323	+2%	+$16.1K	0.16%	96
2018 Q4	$679K	Buy	13,070 +302	+2%	+$16.2K	0.19%	83
2018 Q3	$793K	Buy	12,768 +444	+4%	+$26.3K	0.21%	67
2018 Q2	$682K	Sell	12,324 -1,192	-9%	-$64.4K	0.2%	71
2018 Q1	$838K	Sell	13,516 -194	-1%	-$12.5K	0.25%	57
2017 Q4	$849K	Buy	13,710 +304	+2%	+$19K	0.27%	59
2017 Q3	$860K	Buy	13,406 +6,606	+97%	+$386K	0.29%	55
2017 Q2	$380K	Buy	6,800 +155	+2%	+$8.44K	0.15%	73
2017 Q1	$353K	Buy	6,645 +890	+15%	+$48.8K	0.18%	66
2016 Q4	$327K	Sell	5,755 -80	-1%	-$4.37K	0.2%	58
2016 Q3	$322K	Buy	5,835 +644	+12%	+$41.4K	0.15%	60
2016 Q2	$383K	Buy	+5,191	New	+$367K	0.19%	54

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jacobi Capital Management's BMY Position: Q1 2026 in Review

Jacobi Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 0.74% in Q1 2026, selling an estimated $28.8K and leaving 65,891 shares worth $4M. The position accounts for 0.22% of the portfolio, ranked #81.

Jacobi Capital Management first reported a position in BMY in Q2 2016 and has held it in 40 quarters since. The position peaked at $5.98M in Q4 2021. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Jacobi Capital Management held 65,891 shares of Bristol-Myers Squibb worth $4M as of Q1 2026.
Jacobi Capital Management sold 494 Bristol-Myers Squibb shares in Q1 2026, an estimated $28.8K.
Bristol-Myers Squibb made up 0.22% of Jacobi Capital Management's portfolio in Q1 2026, its #81 holding.
Jacobi Capital Management first reported a position in Bristol-Myers Squibb in Q2 2016 and has held it in 40 quarters since.
Jacobi Capital Management's Bristol-Myers Squibb position peaked at $5.98M in Q4 2021.
2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Jacobi Capital Management's 13F filing for Q1 2026, filed 14 May 2026.